Nkarta rises on FDA agreement for amended trial protocol [Seeking Alpha]
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers [Yahoo! Finance]
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
Nkarta to Participate in Needham Virtual Healthcare Conference
Nkarta (NKTX) had its price target lowered by Mizuho from $14.00 to $12.00. They now have an "outperform" rating on the stock.